One in five women suffering from breast cancer has a particularly aggressive, rapidly growing HER2-positive type of tumor. And usually, surgery, chemotherapy and/or targeted year-long therapy are the available treatments. But now a study conducted by experts from India's Tata Memorial cancer research institute indicates that a shorter, targeted therapy ranging between three and six months is 'non-inferior to its […]
